VNDA — Vanda Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual income statement for Vanda Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	248	269	254	193	199
Cost of Revenue
Gross Profit	225	243	230	178	187
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	221	227	248	207	239
Operating Profit	27.2	42.2	6.33	-14	-40.7
Other Net Non Operating Costs
Net Income Before Taxes	31.7	42.4	11.3	6.34	-22.9
Provision for Income Taxes
Net Income After Taxes	23.3	33.2	6.28	2.51	-18.9
Net Income Before Extraordinary Items
Net Income	23.3	33.2	6.28	2.51	-18.9
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	23.3	33.2	6.28	2.51	-18.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.515	0.855	0.11	0.044	-0.325